Articles from EndoQuest Robotics, Inc.

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that enrollment in its pivotal multicenter investigational device exemption (IDE) clinical study, the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine), has concluded after the completion of 50 robotic endoscopic submucosal dissection (ESD) procedures across 49 subjects (Clinicaltrials.gov). Preliminary results for the trial were presented at the 2026 Society of Robotic Surgery (SRS) Annual Meeting.

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that Baylor St. Luke’s Medical Center has been activated as a trial site and has successfully completed its first procedures in the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine), a pivotal multicenter clinical study (Clinicaltrials.gov).

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the next and final stage of its pivotal multicenter trial, the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine). The PARADIGM Trial is an Investigational Device Exemption (IDE) study evaluating EndoQuest’s Endoluminal Surgical (ELS) System for use in endoscopic submucosal dissection (ESD) (Clinicaltrials.gov).

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced new initiatives as part of their collaboration with NVIDIA to integrate NVIDIA IGX Thor, an NVIDIA Blackwell-powered, enterprise-ready platform, into EndoQuest’s next-generation robotic system.